Developer docs
API playgroundTry for free, no card

Search company profiles

TAMM Net

Full company profile

uuid000e5yl

Namestring
TAMM Net
Legal namestring
TAMM Net, Inc.
Websiteurl
tammnet.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

TAMM Net is a boutique clinical research organization (CRO) founded in 2009 in Atlanta, Georgia, by Arthur F. Spalding, providing integrated regulatory, reimbursement, and clinical development services to medical device manufacturers and biomedical innovators. Its service portfolio spans Regulatory and Quality (FDA 510(k) submissions, IDE approvals, CE Mark filings, Quality Management System development), Managed Markets and Reimbursement (coding strategies, payer assessments, C-code applications), Prior Authorization support, Health Economics Outcomes Research, Clinical Research Services (trial design, protocol authoring, principal investigator recruitment, FDA IDE submissions), and a Reimbursement Support Call Center for prior authorizations, benefits verification, and sales force support. The firm operates a proprietary multi-step process framework (8-18 steps) covering Discovery and Requirements, Planning and GAP Analysis, Implementation, Delivery, and Close and Continuation phases.

The business model is professional services revenue, with quote-based, customized engagements sold through direct consultative B2B sales to medical device companies ranging from pre-commercial startups (CivaTech, Atlanta Catheter Therapies, Revolutions Medical, Augment Health, H Robotics, Pro2Cool TecTraum, BioChip Labs, ImmutriX Therapeutics) to mid-market players (Myelotec) and enterprise/government-adjacent clients (Wright Brothers Institute). The company generates revenue across three streams: Regulatory and Quality Services, Reimbursement and Market Access Services, and Clinical Development and Research Services, each priced per engagement rather than through published rate cards. Marketing is conducted via the company website, client testimonials, case studies, and industry recognition, including the 2022 Globe Award from the Georgia Department of Economic Development for international market expansion.

On April 1, 2026, Walnut Hill Medical acquired TAMM Net, with founder and CEO Art Spalding transitioning to Chief Operating Officer of the acquiring organization. Following the transaction, the TAMM Net brand has been folded into Walnut Hill Medical, positioning the CRO's regulatory, reimbursement, prior authorization, and provider training capabilities within a larger commercialization-focused organization serving emerging and commercial-stage medical device companies.

Short descriptiontext

TAMM Net is a boutique Atlanta-based clinical research organization that provides regulatory, reimbursement, prior authorization, HEOR, and clinical trial services to medical device and biomedical innovators. Founded in 2009, it was acquired by Walnut Hill Medical in April 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device CRO, regulatory consulting, reimbursement strategy, FDA submission services, biomedical market access
Industry1 code
PRIMARYHLAGAOAH
Clinical Trial Supply, Logistics & Vendor Management FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Other Scientific and Technical Consulting Services541690
  • All Other Professional, Scientific, and Technical Services54199
SIC code1 code
  • Services-Health Services8000
Product category
Medical Device Regulatory and Reimbursement Consulting (CRO Services)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Regulatory and Quality Services
TypeProfessional Services
Description

Regulatory strategy development, FDA submissions, 510(k) applications, IDE approvals, and quality management system development for medical device manufacturers.

tammnet.com
2Reimbursement and Market Access Services
TypeProfessional Services
Description

Managed markets strategy, prior authorization support, reimbursement guides, coding applications (C-codes), and payer assessments to help clients achieve reimbursement for their products.

tammnet.com
3Clinical Development and Research Services
TypeProfessional Services
Description

Clinical trial design and conduct, protocol development, principal investigator recruitment, and FDA interaction support for regulatory clearance.

tammnet.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TAMM Net is a boutique clinical research organization that delivers integrated regulatory and market access services to biomedical manufacturers from concept through commercialization. Its core offerings include Regulatory and Quality services (FDA submissions, 510(k), CE Mark, QMS development), Managed Markets and Reimbursement (coding, payer assessments, prior authorization, reimbursement call center), Health Economics Outcomes Research, and Clinical Research Services (trial design, protocol authoring, IDE submissions, PI recruitment).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • $244,479 grant obtained on first application for Atlanta Catheter Therapies
+2 more records
Product overview1 text field

TAMM Net is a boutique Clinical Research Organization (CRO) providing integrated regulatory and market access services to biomedical manufacturers. The company operates as a single unified service offering encompassing Regulatory & Quality (FDA submissions, CE Mark, quality management systems), Managed Markets & Reimbursement, Prior Authorization Services, Health Economics Outcomes Research, Reimbursement Support Call Center, and Clinical Research Services. The company was acquired by Walnut Hill Medical in April 2026, with CEO Art Spalding becoming COO of the acquiring company.

Product and service1 record
1Regulatory and Quality Services
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Walnut Hill Medical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Walnut Hill Medical acquired TAMM Net, finalizing the transaction on April 1, 2026. The acquisition strengthens WHM's capabilities in regulatory submissions, reimbursement strategy, prior authorization support, and provider training—functions critical for medical device commercialization and sustained market access. As part of the transaction, TAMM Net CEO Art Spalding joined Walnut Hill Medical as Chief Operating Officer. The combined organization aims to better serve emerging innovators and commercial-stage medical device companies seeking disciplined commercialization execution in complex markets.

desmoinesregister.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1NAMSA
TypeDirect peer
Description

NAMSA is the largest medical device-focused CRO providing regulatory, clinical, and quality consulting for medtech manufacturers. Directly comparable to TAMM Net as a medtech-specialized services firm, though significantly larger in scale and global footprint.

TypeDirect peer
Description

MCRA is a leading medtech-focused regulatory, clinical, and reimbursement consultancy serving device manufacturers across multiple therapeutic areas. Closely mirrors TAMM Net's integrated regulatory + reimbursement + clinical offering for emerging and commercial-stage medtech clients.

TypeDirect peer
Description

Veranex is a medtech CRO offering regulatory, clinical, design, and commercialization services to medical device innovators. Comparable to TAMM Net's end-to-end commercialization support stack for medical device manufacturers.

4RCRI (Regulatory & Clinical Research Institute)
TypeDirect peer
Description

RCRI provides regulatory affairs, clinical research, and quality systems consulting specifically to medical device and combination product companies. Direct peer in medtech-focused boutique consulting with overlapping service lines.

TypeDirect peer
Description

Boston MedTech Advisors is a medtech consultancy providing regulatory, reimbursement, and clinical strategy to device manufacturers. Comparable boutique positioning and service mix to TAMM Net for emerging medtech clients.

TypeDirect peer
Description

MEDIcept is a regulatory, quality, and clinical consulting firm serving medical device and combination product manufacturers. Overlapping service portfolio with TAMM Net, particularly in regulatory submissions and quality systems development.

TypeBroad incumbent
Description

IQVIA is a global CRO and life sciences services giant offering regulatory, clinical, and commercial services across pharma and medtech. Operates broadly in the same space as TAMM Net but at significantly greater scale and with broader therapeutic and geographic coverage.

TypeBroad incumbent
Description

Medpace is a mid-to-large CRO providing full-service clinical development and regulatory support to biopharma and medtech sponsors. Comparable regulatory and clinical offerings, though with broader scale and a pharma-heavy mix.

TypeBroad incumbent
Description

Premier Research is a global CRO serving biotech, pharma, and medtech with regulatory and clinical services. Overlapping medtech regulatory and clinical trial service lines with TAMM Net at a broader scale.

TypeEmerging player
Description

Advarra provides clinical research services including IRB review, biosafety, and clinical technology to medtech and biopharma sponsors. Partial overlap with TAMM Net's clinical research offering for device manufacturers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TAMM Net

Medical Device Regulatory and Reimbursement Consulting (CRO Services)tammnet.com

TAMM Net is a boutique Atlanta-based clinical research organization that provides regulatory, reimbursement, prior authorization, HEOR, and clinical trial services to medical device and biomedical innovators. Founded in 2009, it was acquired by Walnut Hill Medical in April 2026.

What TAMM Net does

TAMM Net is a boutique clinical research organization (CRO) founded in 2009 in Atlanta, Georgia, by Arthur F. Spalding, providing integrated regulatory, reimbursement, and clinical development services to medical device manufacturers and biomedical innovators. Its service portfolio spans Regulatory and Quality (FDA 510(k) submissions, IDE approvals, CE Mark filings, Quality Management System development), Managed Markets and Reimbursement (coding strategies, payer assessments, C-code applications), Prior Authorization support, Health Economics Outcomes Research, Clinical Research Services (trial design, protocol authoring, principal investigator recruitment, FDA IDE submissions), and a Reimbursement Support Call Center for prior authorizations, benefits verification, and sales force support. The firm operates a proprietary multi-step process framework (8-18 steps) covering Discovery and Requirements, Planning and GAP Analysis, Implementation, Delivery, and Close and Continuation phases.

The business model is professional services revenue, with quote-based, customized engagements sold through direct consultative B2B sales to medical device companies ranging from pre-commercial startups (CivaTech, Atlanta Catheter Therapies, Revolutions Medical, Augment Health, H Robotics, Pro2Cool TecTraum, BioChip Labs, ImmutriX Therapeutics) to mid-market players (Myelotec) and enterprise/government-adjacent clients (Wright Brothers Institute). The company generates revenue across three streams: Regulatory and Quality Services, Reimbursement and Market Access Services, and Clinical Development and Research Services, each priced per engagement rather than through published rate cards. Marketing is conducted via the company website, client testimonials, case studies, and industry recognition, including the 2022 Globe Award from the Georgia Department of Economic Development for international market expansion.

On April 1, 2026, Walnut Hill Medical acquired TAMM Net, with founder and CEO Art Spalding transitioning to Chief Operating Officer of the acquiring organization. Following the transaction, the TAMM Net brand has been folded into Walnut Hill Medical, positioning the CRO's regulatory, reimbursement, prior authorization, and provider training capabilities within a larger commercialization-focused organization serving emerging and commercial-stage medical device companies.

TAMM Net firmographics

Firmographics
Name
TAMM Net
Legal name
TAMM Net, Inc.
Website
https://tammnet.com
Company type
Private
Founded year
2009
Operating status
Acquired
Headcount range
1–10 employees
Short description
TAMM Net is a boutique Atlanta-based clinical research organization that provides regulatory, reimbursement, prior authorization, HEOR, and clinical trial services to medical device and biomedical innovators. Founded in 2009, it was acquired by Walnut Hill Medical in April 2026.
Ownership category
akta.pro rank

TAMM Net industry classification

Industry
Product category
Medical Device Regulatory and Reimbursement Consulting (CRO Services)
NAICS
Other Scientific and Technical Consulting Services (541690), All Other Professional, Scientific, and Technical Services (54199)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAOAH
Clinical Trial Supply, Logistics & Vendor Management FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Medical device CRO
  • Regulatory consulting
  • Reimbursement strategy
  • FDA submission services
  • Biomedical market access

Where TAMM Net is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TAMM Net business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Regulatory and Quality Services: Regulatory strategy development, FDA submissions, 510(k) applications, IDE approvals, and quality management system development for medical device manufacturers.
  2. Reimbursement and Market Access Services: Managed markets strategy, prior authorization support, reimbursement guides, coding applications (C-codes), and payer assessments to help clients achieve reimbursement for their products.
  3. Clinical Development and Research Services: Clinical trial design and conduct, protocol development, principal investigator recruitment, and FDA interaction support for regulatory clearance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

TAMM Net product offering

Product offering

Core offering

TAMM Net is a boutique clinical research organization that delivers integrated regulatory and market access services to biomedical manufacturers from concept through commercialization. Its core offerings include Regulatory and Quality services (FDA submissions, 510(k), CE Mark, QMS development), Managed Markets and Reimbursement (coding, payer assessments, prior authorization, reimbursement call center), Health Economics Outcomes Research, and Clinical Research Services (trial design, protocol authoring, IDE submissions, PI recruitment).

Product overview

TAMM Net is a boutique Clinical Research Organization (CRO) providing integrated regulatory and market access services to biomedical manufacturers. The company operates as a single unified service offering encompassing Regulatory & Quality (FDA submissions, CE Mark, quality management systems), Managed Markets & Reimbursement, Prior Authorization Services, Health Economics Outcomes Research, Reimbursement Support Call Center, and Clinical Research Services. The company was acquired by Walnut Hill Medical in April 2026, with CEO Art Spalding becoming COO of the acquiring company.

Differentiator

Problem solved

Functional benefit

Products and services

  • Regulatory and Quality Services

Quantifiable outcome

  • $244,479 grant obtained on first application for Atlanta Catheter Therapies
  • +2 more outcomes

Companies that use TAMM Net

Customer profile

Named customers10 records

Segments2 records

Ideal customer profiles2 records

TAMM Net technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

TAMM Net partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Walnut Hill MedicalcoreStrategic or Co-development Partner · 1 April 2026Walnut Hill Medical acquired TAMM Net, finalizing the transaction on April 1, 2026. The acquisition strengthens WHM's capabilities in regulatory submissions, reimbursement strategy, prior authorization support, and provider training—functions critical for medical device commercialization and sustained market access. As part of the transaction, TAMM Net CEO Art Spalding joined Walnut Hill Medical as Chief Operating Officer. The combined organization aims to better serve emerging innovators and commercial-stage medical device companies seeking disciplined commercialization execution in complex markets.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

TAMM Net competitors and assessment

Company assessment

Direct peers

  • NAMSA: NAMSA is the largest medical device-focused CRO providing regulatory, clinical, and quality consulting for medtech manufacturers. Directly comparable to TAMM Net as a medtech-specialized services firm, though significantly larger in scale and global footprint.
  • MCRA (Musculoskeletal Clinical Regulatory Advisers): MCRA is a leading medtech-focused regulatory, clinical, and reimbursement consultancy serving device manufacturers across multiple therapeutic areas. Closely mirrors TAMM Net's integrated regulatory + reimbursement + clinical offering for emerging and commercial-stage medtech clients.
  • Veranex: Veranex is a medtech CRO offering regulatory, clinical, design, and commercialization services to medical device innovators. Comparable to TAMM Net's end-to-end commercialization support stack for medical device manufacturers.
  • RCRI (Regulatory & Clinical Research Institute): RCRI provides regulatory affairs, clinical research, and quality systems consulting specifically to medical device and combination product companies. Direct peer in medtech-focused boutique consulting with overlapping service lines.
  • Boston MedTech Advisors: Boston MedTech Advisors is a medtech consultancy providing regulatory, reimbursement, and clinical strategy to device manufacturers. Comparable boutique positioning and service mix to TAMM Net for emerging medtech clients.
  • MEDIcept: MEDIcept is a regulatory, quality, and clinical consulting firm serving medical device and combination product manufacturers. Overlapping service portfolio with TAMM Net, particularly in regulatory submissions and quality systems development.

Broad incumbents

  • IQVIA: IQVIA is a global CRO and life sciences services giant offering regulatory, clinical, and commercial services across pharma and medtech. Operates broadly in the same space as TAMM Net but at significantly greater scale and with broader therapeutic and geographic coverage.
  • Medpace: Medpace is a mid-to-large CRO providing full-service clinical development and regulatory support to biopharma and medtech sponsors. Comparable regulatory and clinical offerings, though with broader scale and a pharma-heavy mix.
  • Premier Research: Premier Research is a global CRO serving biotech, pharma, and medtech with regulatory and clinical services. Overlapping medtech regulatory and clinical trial service lines with TAMM Net at a broader scale.

Emerging players

  • Advarra: Advarra provides clinical research services including IRB review, biosafety, and clinical technology to medtech and biopharma sponsors. Partial overlap with TAMM Net's clinical research offering for device manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

TAMM Net social profiles

Digital presence

TAMM Net financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TAMM Net leadership team

Management profile

Number of profiles

TAMM Net funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TAMM Net M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TAMM Net

What does TAMM Net do?

TAMM Net is a boutique clinical research organization that delivers integrated regulatory and market access services to biomedical manufacturers from concept through commercialization. Its core offerings include Regulatory and Quality services (FDA submissions, 510(k), CE Mark, QMS development), Managed Markets and Reimbursement (coding, payer assessments, prior authorization, reimbursement call center), Health Economics Outcomes Research, and Clinical Research Services (trial design, protocol authoring, IDE submissions, PI recruitment).

Is TAMM Net a public or private company?

TAMM Net is a private company. It is classified as corporate owned and is currently acquired.

When was TAMM Net founded?

TAMM Net was founded in 2009. It employs 1 to 10 people.

Where is TAMM Net based?

TAMM Net is headquartered in Atlanta, United States, in the North America region.

How does TAMM Net make money?

Three revenue lines are on record. Regulatory and Quality Services are the primary driver. The others are reimbursement and Market Access Services and clinical Development and Research Services.

Who are TAMM Net's main competitors?

Direct peers on record are NAMSA, MCRA (Musculoskeletal Clinical Regulatory Advisers), Veranex, RCRI (Regulatory & Clinical Research Institute), Boston MedTech Advisors and MEDIcept. Broad incumbents are IQVIA, Medpace and Premier Research. Advarra is listed as an emerging player.

Does TAMM Net have an API?

No public API is recorded for TAMM Net.

What industry is TAMM Net in?

TAMM Net's product category is Medical Device Regulatory and Reimbursement Consulting (CRO Services). Its primary akta.pro industry code is HLAGAOAH, Clinical Trial Supply, Logistics & Vendor Management FSP. Its NAICS code is 541690 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireWalnut Hill Medical Acquires TAMM Net, Expanding Medtech Commercialization CapabilitiesWalnut Hill Medical announced the acquisition of TAMM Net, finalized on April 1, 2026, expanding its medtech commercialization capabilities to include prior authorization support, field reimbursement strategy, and provider training. As part of the transaction, TAMM Net CEO Art Spalding will join Walnut Hill Medical as Chief Operating Officer. The combined organization aims to better serve emerging innovators and commercial-stage medical device companies seeking disciplined commercialization execution in complex markets.The Des Moines RegisterWalnut Hill Medical Acquires TAMM Net, Expanding Medtech Commercialization CapabilitiesWalnut Hill Medical announced its acquisition of TAMM Net, an Atlanta-based medtech clinical research organization, with the transaction finalized on April 1, 2026. The acquisition strengthens WHM's capabilities in regulatory submissions, reimbursement strategy, prior authorization support, and provider training—functions critical for medical device commercialization and sustained market access. As part of the transaction, TAMM Net CEO Art Spalding will join Walnut Hill Medical as Chief Operating Officer.GlobeNewswireAlzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage ClinicalsAlzamend Neuro selected TAMM Net to lead its FDA IND application and oversight for CAO22W, an immunotherapeutic biologic for Alzheimer's disease. The company aims to file the IND and conduct a First Stage Clinical Trial, with TAMM Net starting services immediately. The company's goal is to bring a treatment to market at a reasonable cost.